Literature DB >> 11298997

The selective vulnerability of nerve cells in Huntington's disease.

K A Sieradzan1, D M Mann.   

Abstract

It is now more than 7 years since the genetic mutation causing Huntington's disease (HD) was first identified. Unstable CAG expansion in the IT15 gene, responsible for disease, is translated into an abnormally long polyglutamine (polyQ) tract near the N-terminus of the huntingtin protein. The presence of expanded polyQ in the mutant protein leads to its abnormal proteolytic cleavage with liberation of toxic N-terminal fragments that tend to aggregate, probably first in the cytoplasm. Subsequent nuclear translocation of the cleaved mutant huntingtin is associated with formation of intranuclear protein aggregates and neurotoxicity, probably involving apoptotic cascades. These processes, which can be experimentally modelled in cultured neuronal and non-neuronal cells, seem to underlie neurodegeneration in HD, and also other polyQ disorders, such as dentatorubro-pallidoluysian degeneration, spinal and bulbar muscular atrophy and the spinocerebellar ataxias. They do not, however, explain why within the corpus striatum and cerebral cortex certain nerve cells are susceptible to disease and others are not. In the human HD brain, vulnerable pyramidal neurones within the deeper layers of the cerebral cortex frequently contain large intranuclear inclusions composed of N-terminal fragments of huntingtin. Such inclusions are, however, rare within neurones of the striatum, even in the medium spiny neurones preferentially lost from this region. While inclusions per se do not seem to be neurotoxic, they may provide a surrogate marker of molecular pathology. Recent studies indicate that the nuclear accumulation of mutant huntingtin interferes with transcriptional events. Of particular importance may be the effect on the genes encoding neurotransmitter receptor proteins, especially those involved with glutamatergic neurotransmission. Such changes may trigger or facilitate a low-grade, chronic excitotoxicity of the glutamatergic cortical projection neurones on their target cells in the striatum, already partly compromised by the toxic effects of the HD mutation. This combination of insults, for anatomical reasons experienced predominantly by striatal projection neurones, would eventually cause their selective demise.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298997     DOI: 10.1046/j.0305-1846.2001.00299.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  40 in total

Review 1.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 2.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

Review 3.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

4.  Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.

Authors:  Birgit Zucker; Jibrin A Kama; Alexandre Kuhn; Doris Thu; Lianna R Orlando; Anthone W Dunah; Ozgun Gokce; David M Taylor; Johann Lambeck; Bernd Friedrich; Katrin S Lindenberg; Richard L M Faull; Cornelius Weiller; Anne B Young; Ruth Luthi-Carter
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

Review 5.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

6.  Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.

Authors:  Amy B Ryan; Scott O Zeitlin; Heidi Scrable
Journal:  Neurobiol Dis       Date:  2006-09-15       Impact factor: 5.996

7.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

8.  Quantitative measurement of postural sway in mouse models of human neurodegenerative disease.

Authors:  D Hutchinson; V Ho; M Dodd; H N Dawson; A C Zumwalt; D Schmitt; C A Colton
Journal:  Neuroscience       Date:  2007-07-21       Impact factor: 3.590

9.  Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.

Authors:  Udo Rüb; Matthias Hentschel; Katharina Stratmann; Ewout Brunt; Helmut Heinsen; Kay Seidel; Mohamed Bouzrou; Georg Auburger; Henry Paulson; Jean-Paul Vonsattel; Herwig Lange; Horst-Werner Korf; Wilfred den Dunnen
Journal:  Brain Pathol       Date:  2014-03-03       Impact factor: 6.508

Review 10.  The wobbler mouse: a neurodegeneration jigsaw puzzle.

Authors:  Séverine Boillée; Marc Peschanski; Marie-Pierre Junier
Journal:  Mol Neurobiol       Date:  2003-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.